Novel nanomaterials for clinical neuroscience

  • Gilmore J
  • Yi X
  • Quan L
 et al. 
  • 98


    Mendeley users who have this article in their library.
  • 121


    Citations of this article.


Neurodegenerative disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population ages. The field of nanomedicine is rapidly expanding and promises revolutionary advances to the diagnosis and treatment of devastating human diseases. This paper provides an overview of novel nanomaterials that have potential to improve diagnosis and therapy of neurodegenerative disorders. Examples include liposomes, nanoparticles, polymeric micelles, block ionomer complexes, nanogels, and dendrimers that have been tested clinically or in experimental models for delivery of drugs, genes, and imaging agents. More recently discovered nanotubes and nanofibers are evaluated as promising scaffolds for neuroregeneration. Novel experimental neuroprotective strategies also include nanomaterials, such as fullerenes, which have antioxidant properties to eliminate reactive oxygen species in the brain to mitigate oxidative stress. Novel technologies to enable these materials to cross the blood brain barrier will allow efficient systemic delivery of therapeutic and diagnostic agents to the brain. Furthermore, by combining such nanomaterials with cell-based delivery strategies, the outcomes of neurodegenerative disorders can be greatly improved.

Author-supplied keywords

  • Blood-brain barrier
  • Cell-based delivery
  • Nanomaterials
  • Nanotubes/fullerenes
  • Neuroregeneration
  • Neuroscaffolding

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jamie L. Gilmore

  • Xiang Yi

  • Lingdong Quan

  • Alexander V. Kabanov

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free